Advertisement
JYNT vs SRTA
To compare these two companies we present long-term analysis, their fundamental ratings and make comparative short-term technical analysis which are presented below. The conclusion is JYNT is a Hold and SRTA is a StrongBuy.
JYNT in downward trend: price dove below 50-day moving average on September 22, 2026
JYNT moved below its 50-day moving average on September 22, 2026 date and that indicates a change from an upward trend to a downward trend. In 32 of 37 similar past instances, the stock price decreased further within the following month. The odds of a continued downward trend are 86%.
Technical Analysis (Indicators)
Bearish Trend Analysis
The Stochastic Oscillator entered the overbought zone. Expect a price pull-back in the foreseeable future.
The Momentum Indicator moved below the 0 level on October 21, 2026. You may want to consider selling the stock, shorting the stock, or exploring put options on JYNT as a result. In 84 of 107 cases where the Momentum Indicator fell below 0, the stock fell further within the subsequent month. The odds of a continued downward trend are 79%.
Following a 3-day decline, the stock is projected to fall further. Considering past instances where JYNT declined for three days, the price rose further in 50 of 62 cases within the following month. The odds of a continued downward trend are 81%.
The Aroon Indicator for JYNT entered a downward trend on October 21, 2026. This could indicate a strong downward move is ahead for the stock. Traders may want to consider selling the stock or buying put options.
Bullish Trend Analysis
The RSI Oscillator points to a transition from a downward trend to an upward trend -- in cases where JYNT's RSI Oscillator exited the oversold zone, 27 of 40 resulted in an increase in price. Tickeron's analysis proposes that the odds of a continued upward trend are 68%.
The Moving Average Convergence Divergence (MACD) for JYNT just turned positive on October 19, 2026. Looking at past instances where JYNT's MACD turned positive, the stock continued to rise in 31 of 43 cases over the following month. The odds of a continued upward trend are 72%.
Following a +5.21% 3-day Advance, the price is estimated to grow further. Considering data from situations where JYNT advanced for three days, in 160 of 236 cases, the price rose further within the following month. The odds of a continued upward trend are 68%.
JYNT may jump back above the lower band and head toward the middle band. Traders may consider buying the stock or exploring call options.
Fundamental Analysis (Ratings)
The Tickeron PE Growth Rating for this company is 10 (best 1 - 100 worst), pointing to outstanding earnings growth. The PE Growth rating is based on a comparative analysis of stock PE ratio increase over the last 12 months compared against S&P 500 index constituents.
The Tickeron SMR rating for this company is 48 (best 1 - 100 worst), indicating strong sales and a profitable business model. SMR (Sales, Margin, Return on Equity) rating is based on comparative analysis of weighted Sales, Income Margin and Return on Equity values compared against S&P 500 index constituents. The weighted SMR value is a proprietary formula developed by Tickeron and represents an overall profitability measure for a stock.
The Tickeron Seasonality Score of 50 (best 1 - 100 worst) indicates that the company is fair valued in the industry. The Tickeron Seasonality score describes the variance of predictable price changes around the same period every calendar year. These changes can be tied to a specific month, quarter, holiday or vacation period, as well as a meteorological or growing season.
The Tickeron Price Growth Rating for this company is 75 (best 1 - 100 worst), indicating slightly worse than average price growth. JYNT’s price grows at a lower rate over the last 12 months as compared to S&P 500 index constituents.
The Tickeron Valuation Rating of 77 (best 1 - 100 worst) indicates that the company is slightly overvalued in the industry. This rating compares market capitalization estimated by our proprietary formula with the current market capitalization. This rating is based on the following metrics, as compared to industry averages: P/B Ratio (6.398) is normal, around the industry mean (204.137). P/E Ratio (27.577) is within average values for comparable stocks, (19.387). Projected Growth (PEG Ratio) (0.140) is also within normal values, averaging (2.498). Dividend Yield (0.000) settles around the average of (0.095) among similar stocks. P/S Ratio (2.154) is also within normal values, averaging (2.688).
The Tickeron Profit vs. Risk Rating rating for this company is 100 (best 1 - 100 worst), indicating that the returns do not compensate for the risks. JYNT’s unstable profits reported over time resulted in significant Drawdowns within these last five years. A stable profit reduces stock drawdown and volatility. The average Profit vs. Risk Rating rating for the industry is 87, placing this stock worse than average.
SRTA's RSI Oscillator ascending out of oversold territory
The RSI Indicator for SRTA moved out of oversold territory on October 16, 2026. This could be a sign that the stock is shifting from a downward trend to an upward trend. Traders may want to buy the stock or call options. The A.I.dvisor looked at 34 similar instances when the indicator left oversold territory. In 31 of the 34 cases the stock moved higher. This puts the odds of a move higher at 90%.
Technical Analysis (Indicators)
Bullish Trend Analysis
The Momentum Indicator moved above the 0 level on October 21, 2026. You may want to consider a long position or call options on SRTA as a result. In 64 of 75 past instances where the momentum indicator moved above 0, the stock continued to climb. The odds of a continued upward trend are 85%.
The Moving Average Convergence Divergence (MACD) for SRTA just turned positive on October 20, 2026. Looking at past instances where SRTA's MACD turned positive, the stock continued to rise in 41 of 50 cases over the following month. The odds of a continued upward trend are 82%.
Following a +4.18% 3-day Advance, the price is estimated to grow further. Considering data from situations where SRTA advanced for three days, in 204 of 251 cases, the price rose further within the following month. The odds of a continued upward trend are 81%.
SRTA may jump back above the lower band and head toward the middle band. Traders may consider buying the stock or exploring call options.
Bearish Trend Analysis
The Stochastic Oscillator entered the overbought zone. Expect a price pull-back in the foreseeable future.
Following a 3-day decline, the stock is projected to fall further. Considering past instances where SRTA declined for three days, the price rose further in 50 of 62 cases within the following month. The odds of a continued downward trend are 85%.
The Aroon Indicator for SRTA entered a downward trend on October 21, 2026. This could indicate a strong downward move is ahead for the stock. Traders may want to consider selling the stock or buying put options.
Fundamental Analysis (Ratings)
The Tickeron Seasonality Score of 22 (best 1 - 100 worst) indicates that the company is slightly undervalued in the industry. The Tickeron Seasonality score describes the variance of predictable price changes around the same period every calendar year. These changes can be tied to a specific month, quarter, holiday or vacation period, as well as a meteorological or growing season.
The Tickeron PE Growth Rating for this company is 49 (best 1 - 100 worst), pointing to average earnings growth. The PE Growth rating is based on a comparative analysis of stock PE ratio increase over the last 12 months compared against S&P 500 index constituents.
The Tickeron SMR rating for this company is 54 (best 1 - 100 worst), indicating strong sales and a profitable business model. SMR (Sales, Margin, Return on Equity) rating is based on comparative analysis of weighted Sales, Income Margin and Return on Equity values compared against S&P 500 index constituents. The weighted SMR value is a proprietary formula developed by Tickeron and represents an overall profitability measure for a stock.
The Tickeron Valuation Rating of 63 (best 1 - 100 worst) indicates that the company is fair valued in the industry. This rating compares market capitalization estimated by our proprietary formula with the current market capitalization. This rating is based on the following metrics, as compared to industry averages: P/B Ratio (1.492) is normal, around the industry mean (204.137). P/E Ratio (9.612) is within average values for comparable stocks, (19.387). Projected Growth (PEG Ratio) (0.000) is also within normal values, averaging (2.498). Dividend Yield (0.000) settles around the average of (0.095) among similar stocks. P/S Ratio (1.730) is also within normal values, averaging (2.688).
The Tickeron Price Growth Rating for this company is 71 (best 1 - 100 worst), indicating slightly worse than average price growth. SRTA’s price grows at a lower rate over the last 12 months as compared to S&P 500 index constituents.
The Tickeron Profit vs. Risk Rating rating for this company is 100 (best 1 - 100 worst), indicating that the returns do not compensate for the risks. SRTA’s unstable profits reported over time resulted in significant Drawdowns within these last five years. A stable profit reduces stock drawdown and volatility. The average Profit vs. Risk Rating rating for the industry is 87, placing this stock worse than average.
JYNT | SRTA | ||
|---|---|---|---|
OUTLOOK RATING 1..100 | 56 | 22 | |
VALUATION overvalued / fair valued / undervalued 1..100 | 77 Overvalued | 63 Fair valued | |
PROFIT vs RISK RATING 1..100 | 100 | 100 | |
SMR RATING 1..100 | 48 | 54 | |
PRICE GROWTH RATING 1..100 | 75 | 71 | |
P/E GROWTH RATING 1..100 | 10 | 49 | |
SEASONALITY SCORE 1..100 | 50 | 22 |
Tickeron ratings are formulated such that a rating of 1 designates the most successful stocks in a given industry, while a rating of 100 points to the least successful stocks for that industry.
SRTA's Valuation (63) in the null industry is in the same range as JYNT (77) in the Hospital Or Nursing Management industry. This means that SRTA’s stock grew similarly to JYNT’s over the last 12 months.
SRTA's Profit vs Risk Rating (100) in the null industry is in the same range as JYNT (100) in the Hospital Or Nursing Management industry. This means that SRTA’s stock grew similarly to JYNT’s over the last 12 months.
JYNT's SMR Rating (48) in the Hospital Or Nursing Management industry is in the same range as SRTA (54) in the null industry. This means that JYNT’s stock grew similarly to SRTA’s over the last 12 months.
SRTA's Price Growth Rating (71) in the null industry is in the same range as JYNT (75) in the Hospital Or Nursing Management industry. This means that SRTA’s stock grew similarly to JYNT’s over the last 12 months.
JYNT's P/E Growth Rating (10) in the Hospital Or Nursing Management industry is somewhat better than the same rating for SRTA (49) in the null industry. This means that JYNT’s stock grew somewhat faster than SRTA’s over the last 12 months.
| JYNT | SRTA | |
|---|---|---|
| RSI ODDS (%) | 2 days ago 68% | 2 days ago 90% |
| Stochastic ODDS (%) | 2 days ago 80% | 2 days ago 81% |
| Momentum ODDS (%) | 2 days ago 79% | 2 days ago 85% |
| MACD ODDS (%) | 2 days ago 72% | 2 days ago 82% |
| TrendWeek ODDS (%) | 2 days ago 68% | 2 days ago 84% |
| TrendMonth ODDS (%) | 2 days ago 80% | 2 days ago 81% |
| Advances ODDS (%) | 4 days ago 68% | 2 days ago 81% |
| Declines ODDS (%) | 2 days ago 81% | 9 days ago 85% |
| BollingerBands ODDS (%) | 2 days ago 76% | 2 days ago 88% |
| Aroon ODDS (%) | 2 days ago 85% | 2 days ago 79% |
Long-Term Analysis
It is best to consider a long-term outlook for a ticker by using Fundamental Analysis (FA) ratings. The rating of 1 to 100, where 1 is best and 100 is worst, is divided into thirds. The first third (a green rating of 1-33) indicates that the ticker is undervalued; the second third (a grey number between 34 and 66) means that the ticker is valued fairly; and the last third (red number of 67 to 100) reflects that the ticker is overvalued. We use an FA Score to show how many ratings show the ticker to be undervalued (green) or overvalued (red).
JYNT’s FA Score shows that 1 FA rating(s) are green while SRTA’s FA Score has 0 green FA rating(s).
- JYNT’s FA Score: 1 green, 4 red.
- SRTA’s FA Score: 0 green, 5 red.
Short-Term Analysis
It is best to consider a short-term outlook for a ticker by using Technical Analysis (TA) indicators. We use Odds of Success as the percentage of outcomes which confirm successful trade signals in the past.
If the Odds of Success (the likelihood of the continuation of a trend) for each indicator are greater than 50%, then the generated signal is confirmed. A green percentage from 90% to 51% indicates that the ticker is in a bullish trend. A red percentage from 90% - 51% indicates that the ticker is in a bearish trend. All grey percentages are below 50% and are considered not to confirm the trend signal.
JYNT’s TA Score shows that 4 TA indicator(s) are bullish while SRTA’s TA Score has 5 bullish TA indicator(s).
- JYNT’s TA Score: 4 bullish, 5 bearish.
- SRTA’s TA Score: 5 bullish, 3 bearish.
Price Growth
JYNT (@Hospital/Nursing Management) experienced а +3.91% price change this week, while SRTA (@Hospital/Nursing Management) price change was +8.53% for the same time period.
The average weekly price growth across all stocks in the @Hospital/Nursing Management industry was +1.15%. For the same industry, the average monthly price growth was -3.02%, and the average quarterly price growth was +22.32%.
Reported Earning Dates
JYNT is expected to report earnings on Nov 05, 2026.
SRTA is expected to report earnings on Nov 09, 2026.
Industries' Descriptions
@Hospital/Nursing Management (+1.15% weekly)Hospital/Nursing Management companies own and operate health care facilities. Their operations include nursing homes, acute care facilities, retirement centers and outpatient surgery centers. HCA Healthcare Inc., Alcon Inc. and Universal Health Services, Inc. are some major companies in this industry. Technology has been at the forefront of development of advanced solutions, including quicker diagnoses of complex conditions. Investments in new diagnostics, healthcare IoT, and other healthcare technologies continue to gather momentum in this industry.
Advertisement